CD98-Mediated Adhesive Signaling Enables the Establishment and Propagation of Acute Myelogenous Leukemia

Cancer Cell

Volumn 30, Issue 5, 2016, Pages 792-805

  Bajaj, Jeevisha ^a,b,c   Konuma, Takaaki ^a,b,c   Lytle, Nikki K ^a,b,c   Kwon, Hyog Young ^a,b,c   Ablack, Jailal N ^a   Cantor, Joseph M ^a   Rizzieri, David ^d   Chuah, Charles ^e   Oehler, Vivian G ^f   Broome, Elizabeth H ^a,c   Ball, Edward D ^a,c   van der Horst, Edward H ^g   Ginsberg, Mark H ^a,c   Reya, Tannishtha ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SANFORD CONSORTIUM FOR REGENERATIVE MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e SINGAPORE GENERAL HOSPITAL   (Singapore)

^f USA   (United States)

^g Igenica Inc   (United States)

Author keywords

acute myelogenous leukemia; adhesion; cancer; cancer stem cell; CD98; imaging; integrin; leukemia; microenvironment; SLC3A2

Indexed keywords

BLOCKING ANTIBODY; CD98 ANTIGEN; ANTIBODY;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER STEM CELL; CONTROLLED STUDY; DE NOVO ACUTE MYELOID LEUKEMIA; HUMAN; HUMAN CELL; LETHALITY; LEUKEMIA CELL LINE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR MICROENVIRONMENT; ANIMAL; ANTAGONISTS AND INHIBITORS; CANCER TRANSPLANTATION; CELL ADHESION; CELL PROLIFERATION; DRUG EFFECTS; GENE INACTIVATION; GENETICS; LEUKEMIA, MYELOID, ACUTE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTIBODIES; ANTIGENS, CD98; CELL ADHESION; CELL LINE, TUMOR; CELL PROLIFERATION; GENE KNOCKOUT TECHNIQUES; HUMANS; LEUKEMIA, MYELOID, ACUTE; MICE; NEOPLASM TRANSPLANTATION; NEOPLASTIC STEM CELLS;

EID: 85006041197     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2016.10.003     Document Type: Article

References (58)

1. Bissell, M.J., Radisky, D., Putting tumours in context. Nat. Rev. Cancer 1 (2001), 46–54.
2. Calderwood, D.A., Campbell, I.D., Critchley, D.R., Talins and kindlins: partners in integrin-mediated adhesion. Nat. Rev. Mol. Cell Biol. 14 (2013), 503–517.
3. Cantor, J.M., Ginsberg, M.H., CD98 at the crossroads of adaptive immunity and cancer. J. Cell Sci. 125 (2012), 1373–1382.
4. Cantor, J.M., Ginsberg, M.H., Rose, D.M., Integrin-associated proteins as potential therapeutic targets. Immunol. Rev. 223 (2008), 236–251.
5. Cantor, J., Browne, C.D., Ruppert, R., Feral, C.C., Fassler, R., Rickert, R.C., Ginsberg, M.H., CD98hc facilitates B cell proliferation and adaptive humoral immunity. Nat. Immunol. 10 (2009), 412–419.
6. Cantor, J., Slepak, M., Ege, N., Chang, J.T., Ginsberg, M.H., Loss of T cell CD98 H chain specifically ablates T cell clonal expansion and protects from autoimmunity. J. Immunol. 187 (2011), 851–860.
7. Desgrosellier, J.S., Cheresh, D.A., Integrins in cancer: biological implications and therapeutic opportunities. Nat. Rev. Cancer 10 (2010), 9–22.
8. Desgrosellier, J.S., Barnes, L.A., Shields, D.J., Huang, M., Lau, S.K., Prevost, N., Tarin, D., Shattil, S.J., Cheresh, D.A., An integrin alpha(v)beta(3)-c-Src oncogenic unit promotes anchorage-independence and tumor progression. Nat. Med. 15 (2009), 1163–1169.
9. Despeaux, M., Chicanne, G., Rouer, E., De Toni-Costes, F., Bertrand, J., Mansat-De Mas, V., Vergnolle, N., Eaves, C., Payrastre, B., Girault, J.A., et al. Focal adhesion kinase splice variants maintain primitive acute myeloid leukemia cells through altered Wnt signaling. Stem Cells 30 (2012), 1597–1610.
10. Ding, L., Saunders, T.L., Enikolopov, G., Morrison, S.J., Endothelial and perivascular cells maintain haematopoietic stem cells. Nature 481 (2012), 457–462.
11. Doepfner, K.T., Spertini, O., Arcaro, A., Autocrine insulin-like growth factor-I signaling promotes growth and survival of human acute myeloid leukemia cells via the phosphoinositide 3-kinase/Akt pathway. Leukemia 21 (2007), 1921–1930.
12. Estrach, S., Lee, S.A., Boulter, E., Pisano, S., Errante, A., Tissot, F.S., Cailleteau, L., Pons, C., Ginsberg, M.H., Feral, C.C., CD98hc (SLC3A2) loss protects against ras-driven tumorigenesis by modulating integrin-mediated mechanotransduction. Cancer Res. 74 (2014), 6878–6889.
13. Fenczik, C.A., Sethi, T., Ramos, J.W., Hughes, P.E., Ginsberg, M.H., Complementation of dominant suppression implicates CD98 in integrin activation. Nature 390 (1997), 81–85.
14. Fenczik, C.A., Zent, R., Dellos, M., Calderwood, D.A., Satriano, J., Kelly, C., Ginsberg, M.H., Distinct domains of CD98hc regulate integrins and amino acid transport. J. Biol. Chem. 276 (2001), 8746–8752.
15. Feral, C.C., Nishiya, N., Fenczik, C.A., Stuhlmann, H., Slepak, M., Ginsberg, M.H., CD98hc (SLC3A2) mediates integrin signaling. Proc. Natl. Acad. Sci. USA 102 (2005), 355–360.
16. Feral, C.C., Zijlstra, A., Tkachenko, E., Prager, G., Gardel, M.L., Slepak, M., Ginsberg, M.H., CD98hc (SLC3A2) participates in fibronectin matrix assembly by mediating integrin signaling. J. Cell Biol. 178 (2007), 701–711.
17. Fox, R.G., Lytle, N.K., Jaquish, D.V., Park, F.D., Ito, T., Bajaj, J., Koechlein, C.S., Zimdahl, B., Yano, M., Kopp, J.L., et al. Image-based detection and targeting of therapy resistance in pancreatic adenocarcinoma. Nature 534 (2016), 407–411.
18. Guzman, M.L., Neering, S.J., Upchurch, D., Grimes, B., Howard, D.S., Rizzieri, D.A., Luger, S.M., Jordan, C.T., Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 98 (2001), 2301–2307.
19. Hara, K., Kudoh, H., Enomoto, T., Hashimoto, Y., Masuko, T., Malignant transformation of NIH3T3 cells by overexpression of early lymphocyte activation antigen CD98. Biochem. Biophys. Res. Commun. 262 (1999), 720–725.
20. Hayes, G.M., Chinn, L., Cantor, J.M., Cairns, B., Levashova, Z., Tran, H., Velilla, T., Duey, D., Lippincott, J., Zachwieja, J., et al. Antitumor activity of an anti-CD98 antibody. Int. J. Cancer 137 (2014), 710–720.
21. Haynes, B.F., Hemler, M.E., Mann, D.L., Eisenbarth, G.S., Shelhamer, J., Mostowski, H.S., Thomas, C.A., Strominger, J.L., Fauci, A.S., Characterization of a monoclonal antibody (4F2) that binds to human monocytes and to a subset of activated lymphocytes. J. Immunol. 126 (1981), 1409–1414.
22. Henderson, N.C., Collis, E.A., Mackinnon, A.C., Simpson, K.J., Haslett, C., Zent, R., Ginsberg, M., Sethi, T., CD98hc (SLC3A2) interaction with beta 1 integrins is required for transformation. J. Biol. Chem. 279 (2004), 54731–54741.
23. Imai, H., Kaira, K., Oriuchi, N., Shimizu, K., Tominaga, H., Yanagitani, N., Sunaga, N., Ishizuka, T., Nagamori, S., Promchan, K., et al. Inhibition of L-type amino acid transporter 1 has antitumor activity in non-small cell lung cancer. Anticancer Res. 30 (2010), 4819–4828.
24. Jacamo, R., Chen, Y., Wang, Z., Ma, W., Zhang, M., Spaeth, E.L., Wang, Y., Battula, V.L., Mak, P.Y., Schallmoser, K., et al. Reciprocal leukemia-stroma VCAM-1/VLA-4-dependent activation of NF-kappaB mediates chemoresistance. Blood 123 (2014), 2691–2702.
25. Jin, L., Hope, K.J., Zhai, Q., Smadja-Joffe, F., Dick, J.E., Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat. Med. 12 (2006), 1167–1174.
26. Koechlein, C.S., Harris, J.R., Lee, T.K., Weeks, J., Fox, R.G., Zimdahl, B., Ito, T., Blevins, A., Jung, S.H., Chute, J.P., et al. High-resolution imaging and computational analysis of haematopoietic cell dynamics in vivo. Nat. Commun., 7, 2016, 12169.
27. Konopleva, M.Y., Jordan, C.T., Leukemia stem cells and microenvironment: biology and therapeutic targeting. J. Clin. Oncol. 29 (2011), 591–599.
28. Krivtsov, A.V., Armstrong, S.A., MLL translocations, histone modifications and leukaemia stem-cell development. Nat. Rev. Cancer 7 (2007), 823–833.
29. Kunisaki, Y., Bruns, I., Scheiermann, C., Ahmed, J., Pinho, S., Zhang, D., Mizoguchi, T., Wei, Q., Lucas, D., Ito, K., et al. Arteriolar niches maintain haematopoietic stem cell quiescence. Nature 502 (2013), 637–643.
30. Kwon, H.Y., Bajaj, J., Ito, T., Blevins, A., Konuma, T., Weeks, J., Lytle, N.K., Koechlein, C.S., Rizzieri, D., Chuah, C., et al. Tetraspanin 3 is required for the development and propagation of acute myelogenous leukemia. Cell Stem Cell 17 (2015), 152–164.
31. Lane, S.W., Wang, Y.J., Lo Celso, C., Ragu, C., Bullinger, L., Sykes, S.M., Ferraro, F., Shterental, S., Lin, C.P., Gilliland, D.G., et al. Differential niche and Wnt requirements during acute myeloid leukemia progression. Blood 118 (2011), 2849–2856.
32. Lee, J.J., Perera, R.M., Wang, H., Wu, D.C., Liu, X.S., Han, S., Fitamant, J., Jones, P.D., Ghanta, K.S., Kawano, S., et al. Stromal response to Hedgehog signaling restrains pancreatic cancer progression. Proc. Natl. Acad. Sci. USA 111 (2014), E3091–E3100.
33. Matsunaga, T., Takemoto, N., Sato, T., Takimoto, R., Tanaka, I., Fujimi, A., Akiyama, T., Kuroda, H., Kawano, Y., Kobune, M., et al. Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat. Med. 9 (2003), 1158–1165.
34. Milella, M., Kornblau, S.M., Estrov, Z., Carter, B.Z., Lapillonne, H., Harris, D., Konopleva, M., Zhao, S., Estey, E., Andreeff, M., Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. J. Clin. Invest. 108 (2001), 851–859.
35. Miller, P.G., Al-Shahrour, F., Hartwell, K.A., Chu, L.P., Jaras, M., Puram, R.V., Puissant, A., Callahan, K.P., Ashton, J., McConkey, M.E., et al. In vivo RNAi screening identifies a leukemia-specific dependence on integrin beta 3 signaling. Cancer Cell 24 (2013), 45–58.
36. Nakasone, E.S., Askautrud, H.A., Kees, T., Park, J.H., Plaks, V., Ewald, A.J., Fein, M., Rasch, M.G., Tan, Y.X., Qiu, J., et al. Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. Cancer Cell 21 (2012), 488–503.
37. Nguyen, H.T., Dalmasso, G., Torkvist, L., Halfvarson, J., Yan, Y., Laroui, H., Shmerling, D., Tallone, T., D'Amato, M., Sitaraman, S.V., et al. CD98 expression modulates intestinal homeostasis, inflammation, and colitis-associated cancer in mice. J. Clin. Invest. 121 (2011), 1733–1747.
38. Orimo, A., Gupta, P.B., Sgroi, D.C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V.J., Richardson, A.L., Weinberg, R.A., Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121 (2005), 335–348.
39. Ozdemir, B.C., Pentcheva-Hoang, T., Carstens, J.L., Zheng, X., Wu, C.C., Simpson, T.R., Laklai, H., Sugimoto, H., Kahlert, C., Novitskiy, S.V., et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 25 (2014), 719–734.
40. Park, S.M., Gonen, M., Vu, L., Minuesa, G., Tivnan, P., Barlowe, T.S., Taggart, J., Lu, Y., Deering, R.P., Hacohen, N., et al. Musashi2 sustains the mixed-lineage leukemia-driven stem cell regulatory program. J. Clin. Invest. 125 (2015), 1286–1298.
41. Petersen, O.W., Ronnov-Jessen, L., Howlett, A.R., Bissell, M.J., Interaction with basement membrane serves to rapidly distinguish growth and differentiation pattern of normal and malignant human breast epithelial cells. Proc. Natl. Acad. Sci. USA 89 (1992), 9064–9068.
42. Rhim, A.D., Oberstein, P.E., Thomas, D.H., Mirek, E.T., Palermo, C.F., Sastra, S.A., Dekleva, E.N., Saunders, T., Becerra, C.P., Tattersall, I.W., et al. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell 25 (2014), 735–747.
43. Rosilio, C., Nebout, M., Imbert, V., Griessinger, E., Neffati, Z., Benadiba, J., Hagenbeek, T., Spits, H., Reverso, J., Ambrosetti, D., et al. L-type amino-acid transporter 1 (LAT1): a therapeutic target supporting growth and survival of T-cell lymphoblastic lymphoma/T-cell acute lymphoblastic leukemia. Leukemia 29 (2014), 1253–1266.
44. Seguin, L., Desgrosellier, J.S., Weis, S.M., Cheresh, D.A., Integrins and cancer: regulators of cancer stemness, metastasis, and drug resistance. Trends Cell Biol. 25 (2015), 234–240.
45. Shennan, D.B., Thomson, J., Inhibition of system L (LAT1/CD98hc) reduces the growth of cultured human breast cancer cells. Oncol. Rep. 20 (2008), 885–889.
46. Shi, J., Wang, E., Zuber, J., Rappaport, A., Taylor, M., Johns, C., Lowe, S.W., Vakoc, C.R., The Polycomb complex PRC2 supports aberrant self-renewal in a mouse model of MLL-AF9;Nras(G12D) acute myeloid leukemia. Oncogene 32 (2013), 930–938.
47. Sison, E.A., Rau, R.E., McIntyre, E., Li, L., Small, D., Brown, P., MLL-rearranged acute lymphoblastic leukaemia stem cell interactions with bone marrow stroma promote survival and therapeutic resistance that can be overcome with CXCR4 antagonism. Br. J. Haematol. 160 (2013), 785–797.
48. Somervaille, T.C., Cleary, M.L., Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia. Cancer Cell 10 (2006), 257–268.
49. Somervaille, T.C., Matheny, C.J., Spencer, G.J., Iwasaki, M., Rinn, J.L., Witten, D.M., Chang, H.Y., Shurtleff, S.A., Downing, J.R., Cleary, M.L., Hierarchical maintenance of MLL myeloid leukemia stem cells employs a transcriptional program shared with embryonic rather than adult stem cells. Cell Stem Cell 4 (2009), 129–140.
50. Swerlick, R.A., Lee, K.H., Li, L.J., Sepp, N.T., Caughman, S.W., Lawley, T.J., Regulation of vascular cell adhesion molecule 1 on human dermal microvascular endothelial cells. J. Immunol. 149 (1992), 698–705.
51. Tavor, S., Petit, I., Porozov, S., Avigdor, A., Dar, A., Leider-Trejo, L., Shemtov, N., Deutsch, V., Naparstek, E., Nagler, A., et al. CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice. Cancer Res. 64 (2004), 2817–2824.
52. Tyner, J.W., Walters, D.K., Willis, S.G., Luttropp, M., Oost, J., Loriaux, M., Erickson, H., Corbin, A.S., O'Hare, T., Heinrich, M.C., et al. RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia. Blood 111 (2008), 2238–2245.
53. Wang, Y., Krivtsov, A.V., Sinha, A.U., North, T.E., Goessling, W., Feng, Z., Zon, L.I., Armstrong, S.A., The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science 327 (2010), 1650–1653.
54. Xu, Q., Simpson, S.E., Scialla, T.J., Bagg, A., Carroll, M., Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood 102 (2003), 972–980.
55. Yagita, H., Masuko, T., Hashimoto, Y., Inhibition of tumor cell growth in vitro by murine monoclonal antibodies that recognize a proliferation-associated cell surface antigen system in rats and humans. Cancer Res. 46 (1986), 1478–1484.
56. Zent, R., Fenczik, C.A., Calderwood, D.A., Liu, S., Dellos, M., Ginsberg, M.H., Class- and splice variant-specific association of CD98 with integrin beta cytoplasmic domains. J. Biol. Chem. 275 (2000), 5059–5064.
57. Zimdahl, B., Ito, T., Blevins, A., Bajaj, J., Konuma, T., Weeks, J., Koechlein, C.S., Kwon, H.Y., Arami, O., Rizzieri, D., et al. Lis1 regulates asymmetric division in hematopoietic stem cells and in leukemia. Nat. Genet. 46 (2014), 245–252.
58. Zuber, J., Shi, J., Wang, E., Rappaport, A.R., Herrmann, H., Sison, E.A., Magoon, D., Qi, J., Blatt, K., Wunderlich, M., et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 478 (2011), 524–528.